Log in

NYSE:RMDResMed Price Target & Analyst Ratings

-0.51 (-0.25 %)
(As of 08/3/2020 04:00 PM ET)
Today's Range
Now: $202.00
50-Day Range
MA: $190.83
52-Week Range
Now: $202.00
Volume745,385 shs
Average Volume483,688 shs
Market Capitalization$29.22 billion
P/E Ratio57.22
Dividend Yield0.77%

Analyst Ratings

ResMed (NYSE:RMD) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for ResMed in the last 12 months. Their average twelve-month price target is $183.33, suggesting that the stock has a possible downside of 9.24%. The high price target for RMD is $200.00 and the low price target for RMD is $174.00. There are currently 3 sell ratings, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score:
Ratings Breakdown: 3 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $183.33$183.33$179.67$134.50
Price Target Upside: 9.24% downside6.14% upside15.68% upside15.39% downside

ResMed (NYSE:RMD) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ResMed (NYSE:RMD) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/3/2020Bank of AmericaDowngradeBuy ➝ UnderperformLow
6/17/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$176.00Low
5/1/2020JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
4/30/2020Needham & Company LLCInitiated CoverageHoldHigh
4/30/2020OppenheimerUpgradeMarket Perform ➝ Outperform$200.00High
3/26/2020Credit Suisse GroupDowngradeOutperform ➝ NeutralHigh
3/24/2020William BlairReiterated RatingBuyLow
2/3/2020CLSAInitiated CoverageUnderperformHigh
1/31/2020UBS GroupDowngradeBuy ➝ Neutral$174.00High
11/22/2019KeyCorpInitiated CoverageSector Weight ➝ Sector WeightLow
7/29/2019Goldman Sachs GroupUpgradeNeutral ➝ BuyMedium
3/20/2019Deutsche BankUpgradeHold ➝ BuyLow
1/28/2019BMO Capital MarketsLower Price TargetOutperform ➝ Positive$120.00High
4/4/2018CitigroupDowngradeBuy ➝ NeutralMedium
1/23/2018Northland SecuritiesUpgradeUnder Perform ➝ Market PerformHigh
1/23/2018MacquarieDowngradeNeutral ➝ SellHigh
10/27/2017BarclaysBoost Price TargetUnderweight$68.00 ➝ $70.00N/A
10/12/2017Jefferies Financial GroupReiterated RatingSell$56.00N/A
(Data available from 8/4/2018 forward)
This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.